UBS Points to Two Top European Luxury Stocks Ahead of 2026 Upswing
Establishment Labs Holdings Inc. has reached a significant milestone as its stock hit a 52-week high, trading at 69.17 USD. This achievement reflects a substantial growth trajectory, with the company’s stock experiencing a remarkable 57.92% increase over the past year. InvestingPro data shows even more impressive gains, with an 85.77% surge over the past six months and a 47.67% rise year-to-date. The Costa Rica-based medical technology company, known for its innovative breast implant solutions, continues to capture investor interest. With a market capitalization of $2 billion and a strong gross profit margin of 68.74%, Establishment Labs maintains a healthy current ratio of 3.33, indicating solid short-term financial stability. The latest price level underscores the market’s confidence in Establishment Labs’ strategic direction and financial performance, positioning the company as a noteworthy player in the healthcare sector. According to InvestingPro analysis, the stock appears slightly overvalued at current levels, with additional ProTips available to subscribers regarding the company’s profitability outlook and valuation metrics.
In other recent news, Establishment Labs Holdings Inc. reported its third-quarter 2025 earnings, exceeding analyst expectations with an earnings per share (EPS) of -$0.38, compared to the forecasted -$0.51. The company’s revenue for the quarter was $53.8 million, surpassing the expected $52.25 million and representing a 33.8% year-over-year growth. U.S. sales reached $11.9 million, exceeding the consensus estimate of $11.2 million. Following these results, Mizuho raised its price target for Establishment Labs to $85.00, maintaining an Outperform rating, citing the better-than-expected third-quarter results. BTIG also increased its price target to $81.00, highlighting the strong adoption of the company’s Motiva implants in the U.S. market. Needham raised its price target to $70.00, noting the company’s revenue and adjusted EBITDA exceeded consensus expectations. Establishment Labs’ management anticipates 2025 revenue to surpass the mid-point of its previous guidance range. These developments reflect a strong outlook for the company, according to several analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.